Reacción a "Pharmaceutical companies Moderna and Merck have announced preliminary successes in the Phase 3 trial of their personalised melanoma vaccine"

“These results are encouraging because they suggest treatments made for an individual patient, even in common conditions, may be moving closer to everyday clinical use. They indicate that highly personalised treatments can be developed, tested and potentially delivered on a much larger scale than previously thought. While this research focuses on cancer, the lessons could have implications far beyond this field, helping build confidence in more tailored approaches to treatment, including for rare conditions that are often driven by unique genetic mutations.”